Molecular Genetics & Genomic Medicine: New Open Access Journal Launched by Wiley
News Nov 06, 2012
Dr. Muenke, a renowned medical geneticist, trained in pediatrics in his native Germany and then pursued postdoctoral fellowship training in human and clinical genetics at Yale and the University of Pennsylvania. He is now based at a leading research organization in Bethesda, USA.
Dr. Muenke’s group identified several genes important in craniofacial disorders including one of the most common, now termed Muenke syndrome. More recently, his lab has identified susceptibility genes for the most common childhood behavioral disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), with further research focused on predicting severity, treatment, and long-term outcome.
Working alongside an international editorial board of experts in diverse areas of human and medical genetics and genomics, Dr. Muenke will oversee the rigorous peer-review and evaluation of articles submitted for publication in MGGM.
“I am extremely excited about being the founding editor of this new journal,” says Dr. Muenke. “Since there is not a single disorder that does not have a genetic origin, I believe that the fields of molecular genetics and genomic medicine will be expanding into virtually all medical specialties. MGGM will grow as well, with articles on diseases from diagnosis to treatment, as a step toward personalized medicine.”
Molecular Genetics & Genomic Medicine is the latest addition to Wiley’s portfolio of genetics journals and will benefit from relationships with widely respected titles including the American Journal of Medical Genetics and Human Mutation.
“We’re delighted to expand our open access portfolio with the addition of this important new journal,” said Rachel Burley, Vice President and Director, Open Access, Wiley. “Under the expert editorial leadership of Dr. Muenke, Molecular Genetics & Genomic Medicine will make a valuable contribution to the literature.”
The journal is open to submissions now and will publish online in spring 2013. Please visit the journal’s website www.MGGMjournal.com for further information and future updates.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.